ChromaDex Initiates Second Human Clinical Study for its Caffeine Ingredient, PURENERGY
date:May 15, 2014
ted energy products have come under increased regulatory and political scrutiny because of the possible risks associated with consuming high amounts of caffeine. PURENERGY offers product formulators a unique solution to reduce total caffeine content while optimizing the consumer experience as well as delivering the benefits of pTeroPure.

Frank L. Jaksch Jr., CEO of ChromaDex, commented, This study will provide additional valuable insight into the benefits of PURENERGY, building on our previous
3/6 next page prev page home page last page
go back |  refresh |  WAP home |  Web page version  | login
07/12 13:48